RASP (Actavia Life Sciences) Retained Earnings: $-28.91 Mil (As of Mar. 2024)


What is Actavia Life Sciences Retained Earnings?

Actavia Life Sciences RASP -87.50% Retained Earnings is $-28.91 Mil as of Mar. 2024.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Actavia Life Sciences's retained earnings for the quarter that ended in Mar. 2024 was $-28.91 Mil.

Actavia Life Sciences's quarterly retained earnings declined from Sep. 2023 ($-28.66 Mil) to Dec. 2023 ($-28.81 Mil) and declined from Dec. 2023 ($-28.81 Mil) to Mar. 2024 ($-28.91 Mil).

Actavia Life Sciences's annual retained earnings declined from Sep. 2021 ($-23.53 Mil) to Sep. 2022 ($-24.22 Mil) and declined from Sep. 2022 ($-24.22 Mil) to Sep. 2023 ($-28.66 Mil).

Actavia Life Sciences  (OTCPK:RASP) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Actavia Life Sciences Retained Earnings Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Retained Earnings Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.31 -22.66 -23.53 -24.22 -28.66

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.50 -28.61 -28.66 -28.81 -28.91

Actavia Life Sciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-28.91 Mil mean?
Actavia Life Sciences (RASP) has a Retained Earnings of $-28.91 Mil as of Mar. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Retained Earnings too high?
Actavia Life Sciences' current Retained Earnings is $-28.91 Mil.
How does Actavia Life Sciences' Retained Earnings compare to BWV and FNCH?
Actavia Life Sciences' Retained Earnings of $-28.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current Retained Earnings is $-28.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Retained Earnings of $-28.91 Mil. The current Retained Earnings is $-28.91 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Retained Earnings is $-28.91 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.